FDA Rejects AstraZeneca's Subcutaneous Lupus Drug Saphnelo Despite EU Approval
Key Insights
The U.S. FDA issued a complete response letter rejecting AstraZeneca's application for a subcutaneous version of lupus therapy Saphnelo, delaying potential approval until the first half of 2026.
The rejection contrasts with the European Union's approval of the self-injectable formulation for adult patients with moderate to severe systemic lupus erythematosus (search) in December 2025.
Despite meeting its primary endpoint in late-stage trials by significantly reducing SLE activity, the subcutaneous version failed to gain FDA approval while the intravenous formulation remains available in over 70 countries.
The U.S. Food and Drug Administration has rejected AstraZeneca's application for a subcutaneous formulation of its lupus therapy Saphnelo, issuing a complete response letter that pushes back the potential approval timeline to the first half of 2026. The setback comes despite the European Union's approval of the self-injectable version in December 2025 for adult patients with moderate to severe systemic lupus erythematosus (search).
Regulatory Divergence Between US and EU
The FDA's rejection stands in stark contrast to regulatory decisions across the Atlantic, where European authorities have already approved the subcutaneous formulation. This divergence highlights the varying regulatory standards between major markets for the same therapeutic approach. AstraZeneca's shares fell by more than 1.5% in early trading following the announcement.
The subcutaneous version would represent a significant advancement in patient care, allowing individuals to self-administer the therapy at home rather than requiring intravenous infusions at clinical facilities. This delivery method could substantially improve treatment convenience and patient compliance for those managing systemic lupus erythematosus (search).
Clinical Success Fails to Convince FDA
The regulatory rejection occurred despite Saphnelo meeting its primary endpoint in late-stage clinical trials, where it significantly reduced disease activity in systemic lupus erythematosus (search). SLE is a chronic autoimmune disease affecting more than 3.4 million people globally, where the immune system attacks healthy tissue and may lead to organ failure.
AstraZeneca has confirmed it provided the additional information requested by the FDA and continues working with the regulator to advance the application. The company emphasized that the intravenous version of Saphnelo, already approved in over 70 countries, remains commercially available.
Financial Impact and Future Development
Saphnelo generated $483 million for AstraZeneca during the first nine months of 2025, representing approximately 1% of the company's total revenue in that period. Under a licensing agreement updated in 2025, AstraZeneca will pay Bristol Myers Squibb (search) royalties on U.S. sales of the therapy.
The company is simultaneously pursuing expanded indications for Saphnelo through ongoing trials in other chronic conditions, including cutaneous lupus erythematosus (search), myositis (search), systemic sclerosis (search), and lupus nephritis (search). These additional development programs could potentially broaden the therapy's market reach beyond its current SLE indication.